875542-01-1Relevant articles and documents
A simple primary amine catalyst for enantioselective α-hydroxylations and α-fluorinations of branched aldehydes
Witten, Michael R.,Jacobsen, Eric N.
, p. 2772 - 2775 (2015/06/16)
A new primary amine catalyst for the asymmetric α-hydroxylation and α-fluorination of α-branched aldehydes is described. The products of the title transformations are generated in excellent yields with high enantioselectivities. Both processes can be performed within short reaction times and on gram scale. The similarity in results obtained in both reactions, combined with computational evidence, implies a common basis for stereoinduction and the possibility of a general catalytic mechanism for α-functionalizations. Promising initial results in α-amination and α-chlorination reactions support this hypothesis.
Benzimidazolones: A new class of selective peroxisome proliferator- activated receptor γ (PPARγ) modulators
Liu, Weiguo,Lau, Fiona,Liu, Kun,Wood, Harold B.,Zhou, Gaochao,Chen, Yuli,Li, Ying,Akiyama, Taro E.,Castriota, Gino,Einstein, Monica,Wang, Chualin,McCann, Margaret E.,Doebber, Thomas W.,Wu, Margaret,Chang, Ching H.,McNamara, Lesley,McKeever, Brian,Mosley, Ralph T.,Berger, Joel P.,Meinke, Peter T.
experimental part, p. 8541 - 8554 (2012/02/04)
A series of benzimidazolone carboxylic acids and oxazolidinediones were designed and synthesized in search of selective PPARγ modulators (SPPARγMs) as potential therapeutic agents for the treatment of type II diabetes mellitus (T2DM) with improved safety profiles relative to rosiglitazone and pioglitazone, the currently marketed PPARγ full agonist drugs. Structure-activity relationships of these potent and highly selective SPPARγMs were studied with a focus on their unique profiles as partial agonists or modulators. A variety of methods, such as X-ray crystallographic analysis, PPARγ transactivation coactivator profiling, gene expression profiling, and mutagenesis studies, were employed to reveal the differential interactions of these new analogues with PPARγ receptor in comparison to full agonists. In rodent models of T2DM, benzimidazolone analogues such as (5R)-5-(3-{[3-(5-methoxybenzisoxazol-3-yl)benzimidazol-1-yl]methyl}phenyl) -5-methylox-azolidinedione (51) demonstrated efficacy equivalent to that of rosiglitazone. Side effects, such as fluid retention and heart weight gain associated with PPARγ full agonists, were diminished with 51 in comparison to rosiglitazone based on studies in two independent animal models. (Figure presented)
BENZOUREAS HAVING ANTI-DIABETIC ACTIVITY
-
Page/Page column 31, (2008/06/13)
Benzourea compounds of Formula I having aryl-(CH2)x-oxazolidinedione or aryl-(CH2)x-thiazolidinedione substituents on one of the N atoms of the benzourea ring, wherein x is 0 or 1, are PPAR gamma agonists or partial agonists and are useful in the treatment and control of type II diabetes, including hyperglycemia and other symptoms such as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity, that are often associated with type 2 diabetes. I